Your email has been successfully added to our mailing list.

×
0.0304506699147381 0.0304506699147381 0.0657734470158342 0.0645554202192447 0.0809987819732033 0.0962241169305724 0.103836784409257 0.10231425091352
Stock impact report

FDA Advisory Committee Votes Unanimously to Support the Use of Teprotumumab for the Treatment of Thyroid Eye Disease (TED)

Horizon Therapeutics Public Limited Company - Ordinary Shares (HZNP) 
Last horizon therapeutics public limited company - ordinary shares earnings: 2/26 07:00 am Check Earnings Report
Company Research Source: Business Wire
-- If approved, teprotumumab would be the first and only approved medicine for people living with TED, fulfilling a significant unmet need -- DUBLIN--(BUSINESS WIRE)--Horizon Therapeutics plc (Nasdaq: HZNP) today announced that the Dermatologic and Ophthalmic Drugs Advisory Committee (DODAC) of the U.S. Food and Drug Administration (FDA) voted unanimously that the potential benefits of teprotumumab, a fully human monoclonal antibody (mAb), outweigh the potential risks for the treatment of Thyroid Eye Disease (TED).TED is a rare, serious, progressive and vision-threatening autoimmune disease, and is associated with proptosis (eye bulging), diplopia (double vision), blurred vision, pain and facial disfigurement that can significantly impact patients’ quality of life. If approved, teprotumumab would be the first FDA-approved medicine for TED. Teprotumumab is an investigational medicine and its safety and efficacy have not been established.“Today’s unanimously positive vote marks a sig Show less Read more
Impact Snapshot
Event Time:
HZNP
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison Updated
Event Day
Stock performance from the time of news release until the following 4pm ET market close
Last price at news event
Since Event
Multi-day stock performance from the time of the news release
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
LAST
PRICE AT
NEWS EVENT
SINCE EVENT
Multi-day stock performance from the time of the news release
Last Price
VWAP
High:
Max Up
High:
Low:
Max Down
Low:
%
Post news range
%
Price change

Price Change Percentage


S&P 500
(SPX)

%

Volume ratio
%

Volume
Ticks

Avg transaction size

Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Opt-in for HZNP alerts
Opt-in for
HZNP alerts

from News Quantified
Opt-in for
HZNP alerts

from News Quantified